Elanco Animal Health Incorporated has announced U.S. Department of Agriculture (USDA) approval of TruCan Ultra B (Oral), an oral vaccine indicated for the protection of dogs against Bordetella bronchiseptica. “We are committed to improving the in-clinic vaccination experience for pets,” says Bobby Modi, Executive Vice President, U.S. Pet Health and Global Digital Transformation at Elanco. “USDA approval of TruCan Ultra B (Oral) strengthens our respiratory vaccine portfolio and demonstrates how Elanco is going beyond to develop innovative solutions that support better experiences for dogs and the veterinary teams who care for them.” The medication is reportedly the first USDA-licensed ½ mL oral Bordetella bronchiseptica vaccine for dogs and is designed to “reduce adverse reactions by removing unwanted protein and debris and to improve patient comfort.” The product is a line extension of TruCan B Oral and is designed to deliver the same antigenic protection in a reduced dose volume. This approval follows USDA clearance of TruCan Ultra CIV H3N2/H3N8 in July 2025. TruCan Ultra B (Oral) is expected to launch in the first quarter of 2026.
